Last reviewed · How we verify

Last 5 amino acids of GLP-1

Elahi, Dariush, PhD · Phase 1 active Small molecule

Last 5 amino acids of GLP-1 is a Small molecule drug developed by Elahi, Dariush, PhD. It is currently in Phase 1 development. Also known as: VTC-G15; LVKGR.

The last five amino acids of GLP-1 are being studied for their potential in treating various conditions, including alcohol use disorder and inflammatory bowel disease. Early-phase trials are underway, with no FDA approval yet. The drug is a peptide cleavage product of GLP-1, offering potential metabolic benefits.

At a glance

Generic nameLast 5 amino acids of GLP-1
Also known asVTC-G15; LVKGR
SponsorElahi, Dariush, PhD
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Last 5 amino acids of GLP-1

What is Last 5 amino acids of GLP-1?

Last 5 amino acids of GLP-1 is a Small molecule drug developed by Elahi, Dariush, PhD.

Who makes Last 5 amino acids of GLP-1?

Last 5 amino acids of GLP-1 is developed by Elahi, Dariush, PhD (see full Elahi, Dariush, PhD pipeline at /company/elahi-dariush-phd).

Is Last 5 amino acids of GLP-1 also known as anything else?

Last 5 amino acids of GLP-1 is also known as VTC-G15; LVKGR.

What development phase is Last 5 amino acids of GLP-1 in?

Last 5 amino acids of GLP-1 is in Phase 1.

Related